|
Malcolm A. S. Moore, D.Phil. (born January 18, 1944) is the Enid A. Haupt Chair of Cell Biology at the Memorial Sloan-Kettering Cancer Center. Dr. Moore is a noted oncologist and hematologist primarily known for being the Principal Investigator in the development of filgrastim, marketed by Amgen under the brand name of Neupogen and Neulasta. Over 3 million patients world-wide, mostly with cancer, have been treated with Neupogen. G-CSF mobilizes stem cells from the bone marrow into the circulation and subsequent peripheral blood leukapheresis produces sufficient stem cells for both autologous or allogeneic transplantation, reducing the need to obtain large volumes of bone marrow. Such stem cell transplants give a faster recovery of white blood cells, platelets and red cells than seen with conventional bone marrow transplantation. G-CSF stem cell transplants are used in treatment of leukemia, lymphoma and multiple myeloma resulting in prolonged remission and, in some cases, cure. He is a member of various national and international societies and is on the editorial boards of a number of Journals. He has served or chaired committees of governmental and professional organizations. == Research == In his early career Dr Moore discovered that all stem cells of the blood and lymphoid system developed in the yolk sac at an early stage of embryo development and migrated via the blood stream to colonize the bone marrow and immune system. All adult blood stem cells derived from this initial source. These discoveries provided a rational for bone marrow transplantation. He was the first (1970) to prove the existence of cancer stem cells in a study of leukemia. Working with Dr. Metcalf in Australia he showed that “colony stimulating factors” were necessary for the growth of normal and leukemic stem cells and progenitor cells. In 1980-82 his group first identified (and provided an in vitro assay for) the human mesenchymal stem cell - the precursor of bone, cartilage, adipose tissue and smooth muscle. In collaboration with Dr . Shahin Raffi in 1994, a bone marrow-derived endothelial progenitor cell was identified and shown to play an important role in the development of the blood supply of developing tumors. In 1983-84 his group succeeded in identifying and purifying a human growth factor, G-CSF, that stimulates white blood cell production (neutrophils). In collaboration with Amgen, recombinant G-CSF (Neupogen) was developed and in 1987 the first clinical studies were begun at Memorial Sloan-Kettering in cancer patients and pediatric patients with a genetic form of neutropenia. G-CSF protected against chemotherapy-induced neutropenia, reducing hospitalization due to severe infections and permitting all patients to receive the optimal doses of chemotherapy. In breast cancer, a significant improvement in patient survival was achieved since G-CSF reduced inter-treatment time. Most recently Dr Moore has been studying the cancer stem cell in lung cancer and ovarian cancer and has developed some novel methods for growing human cancer stem cells ''in vitro'' allowing extensive molecular analysis and identification of targets for therapy designed to eliminate this rare cell population that is responsible for aggressive tumor growth and relapse. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Malcolm A. S. Moore」の詳細全文を読む スポンサード リンク
|